Nivolumab 40 mg in Combination With Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (clinicaltrials.gov) - Oct 8, 2026 - P3 | N=60 | Active, not recruiting | Sponsor: National Research Center for Hematology, Russia | Recruiting ➔ Active, not recruiting | N=100 ➔ 60
Enrollment change • Enrollment closed • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin's Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma
|